IOVA
Iovance Biotherapeutics, Inc. · Healthcare · Biotechnology
$14.22
-0.07% today · +29.27% 1W
Oct 2 close or latest
PreviewWhy it's moving
Underperforming without a clear catalyst yet
- IOVA −0.07% on the last session vs SPY +0.74%: −0.8 pts of stock-specific move.
- Aftermath, big gain (Sep 29): After its 63 big gains in the past 5 years, IOVA typically gained 1.0% over the next day (median) and was higher 56% of the time; half the outcomes fell between -2.9% and +3.5%. An ordinary day: -0.3%. Among S&P 500 stocks after big gains, that ranks #168 of 500.
- 1 Reddit mentions in the past 24 hours, 82% positive over the week.
- 2 analyst actions in the past 10 days (2 positive, 0 negative); latest: Wells Fargo maintained Overweight, raised target $14.00 → $18.00.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Meta Analyst score · Buy (+0.90)
Every firm's latest rating in the past year, each weighted by its age (a 3-month-old call counts half as much as today's), blended with the consensus of 10 analysts (+1.00, counted like 1.5 fresh ratings). 8 firms, 7 with a call in the past 3 months.
| Firm | Latest rating | Date | Weight |
|---|---|---|---|
| Wells Fargo | Overweight | Sep 30, 2026 | 13% |
| HC Wainwright & Co. | Buy | Sep 29, 2026 | 13% |
| Barclays | Overweight | Sep 17, 2026 | 12% |
| TD Cowen | Buy | Aug 25, 2026 | 10% |
| UBS | Neutral | Aug 20, 2026 | 10% |
| Mizuho | Outperform | Aug 18, 2026 | 9% |
| Citizens | Market Outperform | Aug 7, 2026 | 9% |
| Chardan Capital | Buy | May 8, 2026 | 4% |
Mean target
$12.80
-10.0% upside
Median target
$13.50
-5.1% upside
Target range
6.00–20.00
low to high
Analysts
10
as of Oct 5
Price vs. targets
Low $6
Mean $13
High $20
Now $14.22
Consensus
Strong buy 2Buy 6Hold 2Sell 0Strong sell 0
Rating and target changes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Sep 30, 2026 | Wells Fargo | Raised target | Overweight | $14.00 → $18.00 |
| Sep 29, 2026 | HC Wainwright & Co. | Raised target | Buy | $9.00 → $20.00 |
| Sep 17, 2026 | Barclays | Raised target | Overweight | $13.00 → $15.00 |
| Aug 25, 2026 | TD Cowen | Raised target | Buy | $7.00 → $10.00 |
| Aug 20, 2026 | UBS | Raised target | Neutral | $4.00 → $7.00 |
| Aug 18, 2026 | Mizuho | Raised target | Outperform | $10.00 → $11.00 |
| Aug 7, 2026 | Citizens | Raised target | Market Outperform | $5.00 → $8.00 |
| Aug 7, 2026 | Barclays | Raised target | Overweight | $11.00 → $13.00 |
| May 8, 2026 | Chardan Capital | Lowered target | Buy | $16.00 → $14.00 |
| Apr 10, 2026 | Chardan Capital | Reiterated | Buy | $16.00 |
| Mar 5, 2026 | UBS | Raised target | Neutral | $2.00 → $4.00 |
| Mar 3, 2026 | Citizens | Upgrade | Market Perform → Market Outperform | $5.00 |
| Feb 25, 2026 | Citizens | Upgrade | Market Perform → Market Outperform | $5.00 |
| Feb 25, 2026 | Barclays | Raised target | Overweight | $10.00 → $11.00 |
| Dec 17, 2025 | Barclays | Raised target | Overweight | $9.00 → $10.00 |
| Nov 24, 2025 | Barclays | Raised target | Overweight | $4.00 → $9.00 |
| Nov 6, 2025 | Chardan Capital | Lowered target | Buy | $20.00 → $17.00 |
| Oct 29, 2025 | HC Wainwright & Co. | Lowered target | Buy | $20.00 → $9.00 |
Source: Yahoo Finance analyst data, collected daily.